Yazar "Günal, S" seçeneğine göre listele

Listeleniyor 1 - 8 / 8
  • Küçük Resim Yok
    Öğe
    Antibacterial activity of rhodium, iridium, and ruthenium tripodal phosphine complexes
    (Ecv-Editio Cantor Verlag Medizin Naturwissenschaften, 1998) Sülü, M; Küçükbay, H; Durmaz, R; Günal, S
    Twenty-eight rhodium, iridium, or ruthenium complexes were evaluated for their in vitro antibacterial activity against Enterococcus faecalis ATCC 29212, Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922 and Pseudomonaa aeruginosa ATCC 27853. Ten compounds showed an antibacterial activity against Enterococcus faecalis ATCC 29212 and Staphylococcus aureus ATCC 29213 with a range of the minimum inhibitory concentrations (MICs) between 16 and 125 mu g/ml. None of the compounds exhibited antimicrobial activity against the gram-negative strains E. coli ATCC 25922 or Pseudomonas aeruginosa ATCC 29213 with a concentration range between 4 and 500 mu g/ml.
  • Küçük Resim Yok
    Öğe
    Antibacterial and antifungal activities of complexes of ruthenium (II)
    (Georg Thieme Verlag Kg, 1999) Çetinkaya, B; Özdemir, I; Binbasioglu, B; Durmaz, R; Günal, S
    Twenty ruthenium (IT) complexes (1-5) were evaluated for their in vitro antibacterial and antifungal activity against Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 29213), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Candida albicans and Candida tropicalis. Compounds Id! le, Ih, ii and Ij showed more pronounced antimicrobial activity against Gram-positive bacteria and fungi as compared to the nitrogen donor ruthenium complexes; hydrophobic substituents were significantly mon effective. None of the compounds 1-5 exhibited antimicrobial activity against the Gram-negative strains Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC 27853) with the concentrations ranging between 17.5 and 800 mu g/ml.
  • Küçük Resim Yok
    Öğe
    Antifungal activity of rhodium, iridium, and ruthenium tripodal phosphine complexes
    (Luigi Ponzio E Figlio, 2000) Sülü, M; Kücükbay, H; Durmaz, R; Günal, S
    Twenty-eight rhodium, iridium or ruthenium complexes were evaluated for their in vitro antifungal activities against Candida albicans and Candida tropicalis. Fourteen compounds showed an antifungal activity against C, albicans and C. tropicalis with a range of the minimum inhibitor concentrations (MICs) between 16 and 250 mu g/mL.
  • Küçük Resim Yok
    Öğe
    Antifungal activity of some bis-5-methylbenzimidazole compounds
    (Folia Microbiologica, 2003) Küçükbay, H; Durmaz, R; Okyucu, N; Günal, S
    Twenty bis-5-methylbenzimidazole compounds were evaluated for their in vitro antifungal activity against Candida albicans and Candida tropicalis. Except for three all compounds exhibited an antifungal activity against these yeasts over a range of the minimum inhibitory concentration (MIC) between 25 and 800 mg/L.
  • Küçük Resim Yok
    Öğe
    New derivatives of benzimidazole and their antimicrobial activity
    (E I F T Srl, 1999) Cetinkaya, E; Alici, B; Gök, Y; Durmaz, R; Günal, S
    Azolium salts and neutral 2-aryl derivatives of benzimidazole, benzothiazole and benzoxazole were synthesized and compounds were identified by H-1 and C-13 NMR spectroscopy and microanalytical methods. In this work the salts I and the neutral compounds 2 were evaluated for their in vitro antimicrobial activity against standard strains: Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 29213), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Candida albicans and Candida tropicals. The compounds If, Ig, Il, Im, In, 2a, 2b, 2c, 2e, 2f showed antimicrobial activity against Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 29213), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Candida albicans and Candida tropicals, with minimum inhibitory concentrations (MICs) ranging between 50 to 200 mu g/mL. Compounds If, Ig, 11, Im, 2b, 2e showed the highest activity. Benzothiazolium and benzoxazolium salts were more active than 1,3-disubstituted benzimidazolium salts and neutral 2-substituted benzimidazole, benzothiazole and benzoxazole derivatives.
  • Küçük Resim Yok
    Öğe
    Synthesis and antibacterial activities of new bis-benzimidazoles
    (Ecv-Editio Cantor Verlag Medizin Naturwissenschaften, 2004) Küçükbay, H; Durmaz, R; Okuyucu, N; Günal, S; Kazaz, C
    Twenty bis-benzimidazole derivatives were synthesised by the reaction of benzimidazole with appropriate alkyl halides. The compounds synthesised were identified by H-1, C-13-NMR, FT-IR and micro analysis. All compounds studied in this work were screened for their in vitro antibacterial activity against standard strains; Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 29213), Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC 27853). Ten of the compounds were found effective to inhibit the growth of gram-positive bacteria (E. faecalis and S. aureus) at MIC (minimal inhibitory concentration) values between 50-400 mug/ml. Two of the compounds showed MIC values of 200 mug/ml against gram-negative bacteria (E. coli and P aeruginosa).
  • Küçük Resim Yok
    Öğe
    Synthesis of some benzimidazole derivatives and their antibacterial and antifungal activities
    (Ecv-Editio Cantor Verlag Medizin Naturwissenschaften, 2001) Küçükbay, H; Durmaz, R; Güven, M; Günal, S
    A number of new benzimidazole derivatives were synthesized by the reaction of benzimidazole with appropriate alkyl halides. The compounds synthesized were intentified by H-1-NMR, Fourier Transformation Infrared (FT-IR) and micro analysis. All new and related compounds studied in this work were screened for their in vitro antimicrobial activities against the standard strains: Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 29213), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853) and the yeasts Candida albicans and Candida tropicalis. Eleven of the compounds were found effective to inhibit the growth of Gram-positive bacteria (E. faecalis and S. aureus) at MIC values between 12.5-400 mug/ml. None of the compounds exhibited antimicrobial activity against Gram-negative bacteria (E. coli and P. aeruginosa) at the concentrations studied (6.25-800 mug/ml). All compounds (except compound 3) were significantly effective against C. tropicalis with MIC values of 6.25-400 mug/ml. Eight of the tested compounds showed an antifungal activity against C. albicans with a range of the MICs between 50 and 400 mug/ml.
  • Küçük Resim Yok
    Öğe
    Synthesis of some heterocyclic phosphonates and their antibacterial and antifungal activities
    (Council Scientific & Industrial Res, 1999) Mete, A; Sener, S; Kücükbay, H; Günal, S; Durmaz, R
    Fifteen heterocyclic phosphonate derivatives and their starting compounds have been evaluated in vitro for antibacterial and antifungal activities against standard strains: Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 29213), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853) and yeast-like fungi; Candida albicans and Candida tropicalis. The compounds newly synthesised have been identified by H-1-NMR, FT-IR and micro analysis. Among the tested compounds 12, 13, 16, 17, 18, 22 and 23 are found effective to inhibit the growth of Candida albicans and Candida tropicalis at the MICs between 100-800 mu g/mL. The compounds tested here generally do not exhibit considerable antibacterial activity at the concentration studied (100-800 mu g/mL), except compound 18 which exhibits antibacterial activity against gram-positive bacteria at the MIC of 400 mu g/mL.